Document is current
Any future updates will be listed below
-
Authors
Wilcken, Hauke https://orcid.org/0009-0009-6628-2278
Kaier, Klaus
Meyer, Thomas
Waterhouse, Miguel https://orcid.org/0000-0001-7382-4551
Gräßel, Linda
Duque-Afonso, Jesus https://orcid.org/0000-0002-8287-5673
Marks, Reinhard
Wäsch, Ralph https://orcid.org/0000-0002-0813-3444
Finke, Jürgen https://orcid.org/0000-0002-1799-5927
Zeiser, Robert https://orcid.org/0000-0001-6565-3393
Maas-Bauer, Kristina https://orcid.org/0000-0003-1788-2807
Wehr, Claudia https://orcid.org/0000-0002-5037-6175
- License Information
-
More Information
Article History
Received: 7 May 2025
Revised: 3 July 2025
Accepted: 22 July 2025
First Online: 2 August 2025
Competing interests
: JD-A received speaker honoraria from Lilly, Roche, Amgen Abbvie, Beigene, NovoNordisk and AstraZeneca and travel support from Lilly, Roche, AstraZeneca, Alexion, SOBI and Beigene. RZ received honoraria from Novartis, Sanofi, Neovii, medac and Therakos. KMB received travel support from Sanofi. CW received travel grant honoraria or research support from Grifols, Jazz Pharmaceuticals, Takeda and MSD.
: All included patients provided informed consent to scientific analysis of their data. The study and consent procedure were approved by the local ethics committee (review board approval number 22-1490-S, 24-1470-S1) and adhered to the Declaration of Helsinki.
